Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Peritoneal Neoplasms: full-pipeline trial registry
2 of 15 indexed Peritoneal Neoplasms trials are currently recruiting.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 2 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Peritoneal Neoplasms: 15 US clinical trials tracked, 2 recruiting.
Peritoneal Neoplasms is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Corcept Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition peritoneal-neoplasms
OPEN 2 | RECR 13% | LATE 7 | EARLY 8 | RANK #1140 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Drug Addiction (13% recruiting · 15 trials)
Peritoneal Neoplasms lists 2 open slots (13% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Peritoneal Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Peritoneal Neoplasms is recruiting below its size-band peers.
2 of 15 indexed trials (13.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Peritoneal Neoplasms trials is spread across many organizations.
Corcept Therapeutics accounts for 2 of 15 trials (13.3%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Peritoneal Neoplasms enrolment sits around 162 participants.
Median target enrolment is 162 among the 15 trials that report a genuine target (sentinel values excluded). 6 of those (40%) plan for fewer than 100 participants.
-
Peritoneal Neoplasms research is mostly interventional.
15 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Eli Lilly and Company
NCT07213804
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Corcept Therapeutics
NCT06906341
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
Merck Sharp & Dohme
NCT03740165
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
CanariaBio
NCT04498117
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Corcept Therapeutics
NCT05257408
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
New Mexico Cancer Research Alliance
NCT02571725
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
National Cancer Institute (NCI)
NCT05185947
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Arsenal Biosciences
NCT05617755
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Hoffmann-La Roche
NCT03038100
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Janssen Research & Development
NCT01846611
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
Eli Lilly and Company
NCT00191607
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
Pierian Biosciences
NCT00443196
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
Morphotek
NCT00318370
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
Novartis Pharmaceuticals
NCT00035100
Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
CritiTech
NCT00666991
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 5 |
| Phase 3 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Peritoneal Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Peritoneal Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Peritoneal Neoplasms page
15 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Peritoneal Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Corcept Therapeutics sponsors the most Peritoneal Neoplasms trials on record, review their full trial history before evaluating a specific study. See Corcept Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Peritoneal Neoplasms condition card totals 15 registered trials; most-linked intervention Paclitaxel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.